COVID-19 Pandemic - The government presents its daily update
QUÉBEC CITY, June 21, 2021 /CNW Telbec/ - The most recent data on the evolution of COVID-19, in the last 24 hours, in Québec show:
90 new cases, bringing the total number of people infected to 374,011;
361,521 people have recovered;
No new deaths, for a total of 11,191 deaths;
168 hospitalizations, for a decrease of 2;
39 people in intensive care, which remains stable compared to the previous day;
16,307 samples conducted on June 19.
Vaccination
60,990 doses administered are added, that is 57,004 doses in the last 24 hours and 3,986 doses before June 20, for a total of 7,386,401 doses administered in Québec. Outside Québec, a total of 18,196 doses were administered, for a cumulative total of 7,404,597 doses received by Quebecers.
8,285,035 doses received in total.
Summary Data Evolution Table1
Date
Confirmed cases
Deaths2
Hospitalizations
Hospitalizations in intensive care
Tests performed
Administered doses of vaccine3
June 14
105
1
209 (-5)
50 (-4)
24,849
90,899
June 15
153
1
192 (-17)
45 (-5)
24,686
86,623
June 16
161
1
178 (-14)
41 (-4)
22,677
97,781
June 17
127
2
175 (-3)
39 (-2)
19,619
101,905
June 18
160
0
178 (+3)
39
17,300
91,057
June 19
103
0
170 (-8)
39
16,307
71,745
June 20
90
0
168 (-2)
39
NA
57,004
1 Note that the majority of data are presented according to the day they were entered. They are extracted at 4 p.m. at the date shown and cover the preceding 24 hours. However, the availability of the data on samples involves an additional delay of 24 hours and these correspond to the number of samples taken on the date shown.
2 It should also be noted that the data prior to those of the last 24 hours presented in the column Deaths have been adjusted according to the actual dates of death. This explains the variation of some data compared to those presented in previous press releases. The daily death toll is influenced by the time required for the physician to report the death, the time required to complete the investigation to confirm that the death was attributable to COVID-19, and the entry into the system.
3 Note that the number of doses administered may be subject to daily readjustment for the previous days, due to catching up due to a delay in data entry.
A reminder concerning public health instructions:
To limit the spread of the coronavirus as much as possible, it is important to follow basic preventive measures such as hand washing, physical distancing, wearing a face covering and following the instructions in effect in your region.
Remember that in the event of symptoms, it is always essential to isolate yourself and consult one of the self-care guides or call 1-877-644-4545 (or the telephone code corresponding to the region concerned) to find out the measures to be taken.
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...